Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine

Journal of Affective Disorders

Volumn 148, Issue 1, 2013, Pages 84-91

  Kemp, David E ^a   Hert, Marc De ^b   Rahman, Zia ^c   Fyans, Paula ^c   Eudicone, James M ^c   Marler, Sabrina V ^c   Baker, Ross A ^d   Carlson, Berit X ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Lamotrigine; Lithium; Metabolic syndrome; Valproate

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VALPROIC ACID;

ARTICLE; BIPOLAR I DISORDER; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DSM-IV; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OBESITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PIPERAZINES; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 84876983097     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.11.054     Document Type: Article

References (54)

1. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. loria, and S.C. Smith JR Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
2. O.P. Almeida, J. Calver, K. Jamrozik, G.J. Hankey, and L. Flicker Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study American Journal of Geriatric Psychiatry 17 2009 889 898
3. C.L. Bowden, J.R. Calabrese, T.A. Ketter, G.S. Sachs, R.L. White, and T.R. Thompson Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder American Journal of Psychiatry 163 2006 1199 1201
4. C.L. Bowden, J.R. Calabrese, S.L. Mcelroy, L. Gyulai, A. Wassef, F. Petty, H.G. Pope Jr.; J.C. Chou, P.E. Keck Jr.; L.J. Rhodes, A.C. Swann, R.M. Hirschfeld, and P.J. Wozniak A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group Archives of General Psychiatry 57 2000 481 489
5. C.L. Bowden, E. Vieta, K.S. Ice, J.H. Schwartz, P.P. Wang, and M. Versavel Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial Journal of Clinical Psychiatry 71 2010 130 137
6. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi, F.D. Yocca, and P.B. Molinoff Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors Journal of Pharmacology and Experimental Therapeutics 302 2002 381 389
7. J.R. Calabrese, C.L. Bowden, G. Sachs, L.N. Yatham, K. Behnke, O.P. Mehtonen, P. Montgomery, J. Ascher, W. Paska, N. Earl, and J. Deveaugh-Geiss A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder Journal of Clinical Psychiatry 64 2003 1013 1024
8. C.V. Calkin, D.M. Gardner, T. Ransom, and M. Alda The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders Annals of Medicine 2012
9. L. Capuron, and A.H. Miller Cytokines and psychopathology: lessons from interferon-alpha Biological Psychiatry 56 2004 819 824
10. L. Capuron, S. Su, A.H. Miller, J.D. Bremner, J. Goldberg, G.J. Vogt, C. Maisano, L. Jones, N.V. Murrah, and V. Vaccarino Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biological Psychiatry 64 2008 896 900
11. B.X. Carlson, T.A. Ketter, W. Sun, K. Timko, R.D. Mcquade, R. Sanchez, E. Vester-Blokland, and R. Marcus Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392) Bipolar Disorder 14 2012 41 53
12. C.W. Colton, and R.W. Manderscheid Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states Preventing Chronic Disease 3 2006 A42
13. M.C. De Hert, D. Ohen, J. Bobes, M. Cetkovich-Bakmas, S. Leucht, D.M. Ndetei, J.W. Newcomer, R. Uwakwe, I. Asai, H.J. Moller, S. Gautam, J. Detraux, and C.U. Correll Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level World Psychiatry 10 2011 138 151
14. M. De Hert, J.M. Dekker, D. Wood, K.G. Kahl, R.I. Holt, and H.J. Moller Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) European Psychiatry 24 2009 412 424
15. M. De Hert, J. Detraux, R. Van Winkel, W. Yu, and C.U. Correll Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nature Reviews Endocrinology 8 2012 114 126
16. A. Fagiolini, K.N. Chengappa, I. Soreca, and J. Chang Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden CNS Drugs 22 2008 655 669
17. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr.; J.A. Spertus, and F. Costa Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 112 2005 2735 2752
18. Health, N.I.O. 2004. ATP III Update 2004: Implications of Recent Clinical Trials for the ATP III Guidelines. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), National Institutes of Health: National Heart, Lung, and Blood Institute.
19. S. Jordan, V. Koprivica, R. Chen, K. Tottori, T. Kikuchi, and C.A. Altar The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor European Journal of Pharmacology 441 2002 137 140
20. P.E. Keck Jr.; R. Marcus, S. Tourkodimitris, M. Ali, A. Liebeskind, A. Saha, and G. Ingenito A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania American Journal of Psychiatry 160 2003 1651 1658
21. D.E. Kemp Cardiometabolic health in bipolar disorder Psychiatric Annals 42 2012 179 183
22. D.E. Kemp, J.R. Calabrese, Q.V. Tran, A. Pikalov, J.M. Eudicone, and R.A. Baker Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial Journal of Clinical Psychiatry 71 2010 1138 1144
23. D.E. Kemp, K. Gao, P.K. Chan, S.J. Ganocy, R.L. Findling, and J.R. Calabrese Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome Bipolar Disorder 12 2010 404 413
24. D.E. Kemp, O.N. Karayal, J.R. Calabrese, G.S. Sachs, E. Pappadopulos, K.S. Ice, C.O. Siu, and E. Vieta Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles European Neuropsychopharmacology 22 2012 123 131
25. T. Kikuchi, K. Tottori, Y. Uwahodo, T. Hirose, T. Miwa, Y. Oshiro, and S. Morita 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity Journal of Pharmacology and Experimental Therapeutics 274 1995 329 336
26. H. Koponen, J. Jokelainen, S. Keinanen-Kiukaanniemi, E. Kumpusalo, and M. Vanhala Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study Journal of Clinical Psychiatry 69 2008 178 182
27. T.M. Laursen, T. Munk-Olsen, and C. Gasse Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder PLoS One 6 2011 e24597
28. C. Lorenzo, K. Williams, K.J. Hunt, and S.M. Haffner The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes Diabetes Care 30 2007 8 13
29. R. Marcus, A. Khan, L. Rollin, B. Morris, K. Timko, W. Carson, and R. Sanchez Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study Bipolar Disorder 13 2011 133 144
30. R.S. McIntyre, M. Alsuwaidan, B.I. Goldstein, V.H. Taylor, A. Schaffer, S. Beaulieu, and D.E. Kemp The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders Annals of Clinical Psychiatry 24 2012 69 81
31. R.S. McIntyre, M. Danilewitz, S.S. Liauw, D.E. Kemp, H.T. Nguyen, L.S. Kahn, A. Kucyi, J.K. Soczynska, H.O. Woldeyohannes, A. Lachowski, B. Kim, J. Nathanson, M. Alsuwaidan, and V.H. Taylor Bipolar disorder and metabolic syndrome: an international perspective Journal of Affective Disorders 126 2010 366 387
32. R.S. McIntyre, S.L. Mcelroy, J.M. Eudicone, R.A. Forbes, B.X. Carlson, and R.A. Baker A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder Primary Care Companion for CNS Disorders 13 2011
33. R.S. McIntyre, N.L. Rasgon, D.E. Kemp, H.T. Nguyen, C.W. Law, V.H. Taylor, H.O. Woldeyohannes, M.T. Alsuwaidan, J.K. Soczynska, B. Kim, M.T. Lourenco, L.S. Kahn, and B.I. Goldstein Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap Current Diabetes Reports 9 2009 51 59
34. R.S. McIntyre, J.K. Soczynska, J.Z. Konarski, and S.H. Kennedy The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms Expert Opinion on Drug Safety 5 2006 157 168
35. D.L. Musselman, D.H. Lawson, J.F. Gumnick, A.K. Manatunga, S. Penna, R.S. Goodkin, K. Greiner, C.B. Nemeroff, and A.H. Miller Paroxetine for the prevention of depression induced by high-dose interferon alfa New England Journal of Medicine 344 2001 961 966
36. A. Pan, Q. Sun, O.I. Okereke, K.M. Rexrode, R.R. Rubin, M. Lucas, W.C. Willett, J.E. Manson, and F.B. Hu Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults Diabetologia 55 2012 63 72
37. K. Raikkonen, K.A. Matthews, and L.H. Kuller The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 51 2002 1573 1577
38. M.C. Ryan, H.M. Fenster Farin, F. Abbasi, and G.M. Reaven Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease American Journal of Cardiology 102 2008 40 46
39. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.X. Liu, D.R. Sibley, B.L. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
40. V. Simon, R. Van Winkel, and M. De Hert Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review Journal of Clinical Psychiatry 70 2009 1041 1050
41. P. Sleight Debate: subgroup analyses in clinical trials: fun to look at - but don't believe them! Current Controlled Trials in Cardiovascular Medicine 1 2000 25 27
42. R.D. Spurling, J.S. Lamberti, D. Olsen, X. Tu, and W. Tang Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review Journal of Clinical Psychiatry 68 2007 406 409
43. A.D. Stark, S. Jordan, K.A. Allers, R.L. Bertekap, R. Chen, T. Mistry Kannan, T.F. Molski, F.D. Yocca, T. Sharp, T. Kikuchi, and K.D. Burris Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies Psychopharmacology (Berlin) 190 2007 373 382
44. T. Suppes, E. Vieta, S. Liu, M. Brecher, and B. Paulsson Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127) American Journal of Psychiatry 166 2009 476 488
45. A. Szegedi, J.R. Calabrese, L. Stet, M. Mackle, J. Zhao, and J. Panagides Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension Journal of Clinical Psychopharmacology 32 2012 46 55
46. M. Tohen, E. Vieta, G.M. Goodwin, B. Sun, J.D. Amsterdam, M. Banov, A. Shekhar, S.T. Aaronson, L. Bardenstein, I. Grecu-Gabos, V. Tochilov, D. Prelipceanu, H.S. Oliff, L. Kryzhanovskaya, and C. Bowden Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study Journal of Clinical Psychiatry 69 2008 1776 1789
47. C. Torrent, B. Amann, J. Sanchez-Moreno, F. Colom, M. Reinares, M. Comes, A.R. Rosa, J. Scott, and E. Vieta Weight gain in bipolar disorder: pharmacological treatment as a contributing factor Acta Psychiatrica Scandinavica 118 2008 4 18
48. R. van Winkel, M. De Hert, D. van Eyck, L. Hanssens, M. Wampers, A. Scheen, and J. Peuskens Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder Bipolar Disorder 10 2008 342 348
49. Vancampfort, D.; Vansteelandt, K.; Correll, C.U.; Mitchell, A.; De Hert, A.; Sienaert, P.; Probst, M. & De Hert, M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. American Journal of Psychiatry, in press.
50. E. Vieta, R. Owen, C. Baudelet, R.D. Mcquade, R. Sanchez, and R.N. Marcus Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study Current Medical Research and Opinion 26 2010 1485 1496
51. E. Vieta, T. Suppes, I. Eggens, I. Persson, B. Paulsson, and M. Brecher Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126) Journal of Affective Disorders 109 2008 251 263
52. E. Vieta, C. T'joen, R.D. Mcquade, W.H. Carson JR.; R.N. Marcus, R. Sanchez, R. Owen, and L. Nameche Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study American Journal of Psychiatry 165 2008 1316 1325
53. P.J. Weiden Switching antipsychotic medications: not enough, too often, or just right? American Journal of Psychiatry 168 2011 882 884
54. S. Zeugmann, A. Quante, I. Heuser, R. Schwarzer, and I. Anghelescu Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome Journal of Clinical Psychiatry 71 2010 1007 1016